Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center
Clicks: 464
ID: 119437
2003
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
64.5
/100
464 views
265 readers
Trending
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Patients receiving etoposide within four weeks after diagnosis had a good prognosis as five of the seven patients survived compared to one of 13 not treated with etoposide or treated late (chi-square test for survival, P = 0.0095). The Kaplan-Meier analysis showed the 2.5-year survival of 85.7 +/- 1 …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (44 words).
Try re-searching for a better abstract.
| Reference Key |
s2003medicaltreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Imashuku S;Kuriyama K;Sakai R;Nakao Y;Masuda S;Yasuda N;Kawano F;Yakushijin K;Miyagawa A;Nakao T;Teramura T;Tabata Y;Morimoto A;Hibi S;; |
| Journal | medical and pediatric oncology |
| Year | 2003 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
adult
female
male
adolescent
Retrospective Studies
Evaluation Study
histiocytosis
antineoplastic agents
etoposide / therapeutic use*
shinsaku imashuku
phytogenic / therapeutic use*
pmid:12825212
doi:10.1002/mpo.10314
kikuko kuriyama
shigeyoshi hibi
epstein-barr virus infections / complications*
non-langerhans-cell / drug therapy*
non-langerhans-cell / etiology
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.